Novo Nordisk A/S
NVO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NVO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NVO
Novo Nordisk A/S is a global healthcare company specializing in diabetes care, obesity treatment, and rare diseases, with a leading portfolio of GLP-1 therapies and a deep pipeline of metabolic and cardiovascular candidates.
Key risk: Competitive and seasonal dynamics
BioSniper Score
Based on 5 of 6 signals
Market Cap
$201.64B
Cash Runway
—
Lead Asset
awiqli flextouch (Approved)
Next Catalyst
Phase3_Topline · Oct 19, 2026Financial data as of Dec 31, 2025.
Tracking 2 pipeline candidates · 511 clinical trials · 47 catalysts · 2 FDA decisions for Novo Nordisk A/S.
Novo Nordisk A/S is a global healthcare company specializing in diabetes care, obesity treatment, and rare diseases, with a leading portfolio of GLP-1 therapies and a deep pipeline of metabolic and cardiovascular candidates.
- Total revenue of $309,064.0M and net income of $102,434.0M for the fiscal year ended 2025-12-31 [sec].
- Cash and equivalents of $26,464.0M and shareholders' equity of $83,486.0M as of 2025-12-31 [sec].
- Adjusted operating profit growth for 2026 is now expected to be 0% to -6% at CER, driven by improved GLP-1 product sales outlook [sec · filed 2026-08-04].
- Rare disease sales in International Operations increased by 9% at CER in Q1 2026, driven by higher volumes of NovoSeven and Norditropin [sec · filed 2026-05-06].
- Multiple Phase 3 topline readouts are expected through 2026-2027, including semaglutide, cagrilintide, ziltivekimab, and concizumab [catalyst block].
What works
- Strong commercial execution in GLP-1 products, with improved sales outlook driving upward revision of adjusted operating profit growth to 0% to -6% at CER [sec · filed 2026-08-04].
- Robust pipeline with multiple Phase 3 catalysts in obesity, cardiovascular, and rare disease indications, including semaglutide, cagrilintide, and ziltivekimab [catalyst block].
- Rare disease segment showed resilience with 9% CER growth in International Operations in Q1 2026, supported by NovoSeven and Norditropin [sec · filed 2026-05-06].
What to weigh
- Adjusted operating profit growth guidance for 2026 was revised down to 0% to -6% at CER, reflecting targeted investments in R&D and commercial expansion [sec · filed 2026-08-04].
- Rare disease sales in North America decreased by 16% at CER in Q1 2026, mainly due to lower volumes of NovoSeven and Norditropin from de-stocking [sec · filed 2026-05-06].
- The company faces competitive dynamics and potential seasonality in prescription patterns for injectable and oral obesity medications [sec · filed 2026-08-04].
From the filings
Quoted directly from source documents.
Adjusted operating profit growth guidance for 2026 is 0% to -6% at CER.
“Adjusted operating profit growth is now expected to be 0% to -6% at CER”
SEC filings · August 4, 2026
The improved outlook is driven by increased expectations for GLP-1 product sales.
“The improved outlook is driven by increased expectations for GLP-1 product sales.”
SEC filings · August 4, 2026
Rare disease sales in North America decreased 16% at CER in Q1 2026.
“decreased by 16% at CER, mainly driven by lower volumes of NovoSeven ® and Norditropin ® , mainly related to de-stocking in the quarter due to wholesaler buying patterns at the end of 2025.”
SEC filings · May 6, 2026
Catalyst timeline
- 2026-10-19 · Phase3_Topline · semaglutide — Phase 3 Topline: Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutan — Readout of combination therapy for weight management; will inform potential label expansion.
- 2026-12-07 · Phase3_Topline — Phase 3 Topline: Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and A — Pediatric obesity data for semaglutide; could open new market segment.
- 2026-12-14 · Phase3_Topline — Phase 3 Topline: ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute M — Cardiovascular outcomes trial for ziltivekimab; key for inflammation pipeline.
- 2027-01-08 · Phase3_Topline — Phase 3 Topline: Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients W — Heart failure indication for ziltivekimab; expands therapeutic scope.
- 2027-02-08 · Phase3_Topline — Phase 3 Topline: Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Belo — Liraglutide pediatric obesity data; potential label extension.
- 2027-02-21 · Phase3_Topline — Phase 3 Topline: Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors — Concizumab hemophilia data; addresses rare disease unmet need.
- 2027-03-01 · Phase3_Topline — Phase 3 Topline: A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insul — Insulin icodec weekly dosing data; potential diabetes care innovation.
- 2027-06-29 · Phase3_Topline — Phase 3 Topline: Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity — Cagrilintide monotherapy obesity data; expands weight management portfolio.
Risks & what to watch (3)›
Key risks
- Competitive and seasonal dynamics — Potential negative impact on growth of injectable obesity medication category due to competitive dynamics and seasonality [sec · filed 2026-08-04].
- Rare disease revenue volatility — Rare disease sales in North America declined 16% at CER in Q1 2026 due to de-stocking and wholesaler buying patterns [sec · filed 2026-05-06].
- Investment pressure on margins — Targeted investments in R&D and commercial growth opportunities are partly funded by re-investment of savings, pressuring near-term operating profit [sec · filed 2026-08-04].
What to watch
- Phase 3 topline results for semaglutide in weight management for children and adolescents (expected 2026-12-07) [catalyst block].
- Phase 3 topline results for ziltivekimab on cardiovascular outcomes (ARTEMIS, expected 2026-12-14) [catalyst block].
- Phase 3 topline results for cagrilintide in overweight/obesity (expected 2027-06-29) [catalyst block].
- Phase 3 topline results for concizumab in hemophilia A/B with inhibitors (expected 2027-02-21) [catalyst block].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Novo Nordisk A/S through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Novo Nordisk A/S facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 1.80
Lead: Approved
2 candidates
47 upcoming, next in ~50d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,271
Total value held
$12.94B
| Holder | Shares | Value |
|---|---|---|
| susquehanna international group, llp | 31,024,311 | $1.14B |
| citadel advisors llc | 20,139,625 | $740.1M |
| dodge & cox | 19,333,750 | $710.5M |
| franklin resources inc | 16,083,479 | $591.1M |
| jane street group, llc | 12,881,307 | $473.4M |
| morgan stanley | 10,869,200 | $399.4M |
| bank of america corp /de/ | 10,769,699 | $395.8M |
| ubs group ag | 9,428,026 | $346.5M |
| d. e. shaw & co., inc. | 9,311,206 | $342.2M |
| folketrygdfondet | 9,080,820 | $333.7M |
Showing top 10 of 1,271 institutional holders of Novo Nordisk A/S. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 0.4%
- Days to cover
- 0.8
- Shares short
- 13,996,269
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NVO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Novo Nordisk A/S?
Novo Nordisk A/S is a global healthcare company specializing in diabetes care, obesity treatment, and rare diseases, with a leading portfolio of GLP-1 therapies and a deep pipeline of metabolic and cardiovascular candidates.
What is Novo Nordisk A/S's lead drug candidate?
Novo Nordisk A/S's most advanced tracked candidate is awiqli flextouch (Approved).
What is Novo Nordisk A/S's next catalyst?
Novo Nordisk A/S's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutan" — expected October 19, 2026.
Who is the CEO of Novo Nordisk A/S?
Mr. Maziar Mike Doustdar B.A. is the chief executive officer of Novo Nordisk A/S (NVO).
Where is Novo Nordisk A/S headquartered?
Novo Nordisk A/S (NVO) is headquartered in Bagsvaerd, Denmark.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.